Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Post-ERCP pancreatitis: randomized, prospective study comparing a low- and high-osmolality contrast agent

S Sherman1, R H Hawes, S W Rathgaber

  • 1Department of Medicine, Indiana University School of Medicine, Indianapolis.

Gastrointestinal Endoscopy
|July 1, 1994
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.

Alimentary pharmacology & therapeutics·2011
Same author

The influence of variable-stiffness guide wires on basal biliary sphincter of Oddi pressure measured at endoscopic retrograde cholangiopancreatography.

Endoscopy·2010
Same author

Frequency of sphincter of Oddi dysfunction in patients with previously normal sphincter of Oddi manometry studies.

Endoscopy·2009
Same author

Chemotherapy-induced sclerosing cholangitis.

Clinical radiology·2006
Same author

Multicenter comparative trial of the V-scope system for therapeutic ERCP.

Endoscopy·2006
Same author

Recurrence rate of anastomotic biliary strictures in patients who have had previous successful endoscopic therapy for anastomotic narrowing after orthotopic liver transplantation.

Endoscopy·2006

This study found no significant difference in the frequency or severity of post-ERCP pancreatitis between low-osmolality nonionic (iohexol) and high-osmolality ionic (diatrizoate sodium) contrast agents.

Area of Science:

  • Gastroenterology
  • Medical Imaging

Background:

  • Post-ERCP pancreatitis is a complication, with contrast agents potentially contributing to its development.
  • Evaluating different contrast agents may mitigate ERCP-related pancreatitis risks.

Purpose of the Study:

  • To compare the efficacy of low-osmolality nonionic iohexol versus high-osmolality ionic diatrizoate sodium in reducing post-ERCP pancreatitis.
  • To assess the impact of contrast osmolality on pancreatitis frequency and severity.

Main Methods:

  • Prospective, double-blind, randomized study of 690 patients undergoing diagnostic or therapeutic ERCP.
  • Patients received either iohexol or diatrizoate sodium contrast agents.
  • Pancreatitis diagnosis based on elevated serum amylase/lipase and persistent abdominal pain; severity graded by clinical outcomes.

Related Experiment Videos

Main Results:

  • Overall post-ERCP pancreatitis frequency was similar: 7.2% for diatrizoate sodium vs. 7.5% for iohexol.
  • Pancreatitis severity distribution (mild, moderate, severe) was comparable between the two contrast groups.
  • No significant differences in pancreatitis rates or severity were observed within specific ERCP procedure categories.

Conclusions:

  • Low-osmolality nonionic iohexol does not significantly reduce the risk or severity of post-ERCP pancreatitis compared to high-osmolality ionic diatrizoate sodium.
  • Contrast agent osmolality appears not to be a major determinant of post-ERCP pancreatitis incidence or severity.